Ogivri, a biosimilar of Herceptin, launches in the USA

2 December 2019
mylan_big

Netherlands-incorporated Mylan (Nasdaq: MYL) and India’s Biocon (BSE: 532523) have launched Ogivri (trastuzumab-dkst) in the USA, a biosimilar to Roche’s (ROG: SIX) Herceptin.

Roche's super-blockbuster has led in the breast cancer space for a number of years, with consistent annual revenues of around $7 billion.

The drug has faced increasing competition, however, including from Pfizer’s (NYSE: PFE) Ibrance (palbociclib), which has picked up steam in recent years. Ibrance sales have grown to $4.1 billion in 2018.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars